Oncolytic paramyxoviruses-induced autophagy; A prudent weapon for cancer therapy by Keshavarz, M et al.
REVIEW Open Access
Oncolytic paramyxoviruses-induced
autophagy; a prudent weapon for cancer
therapy
Mohsen Keshavarz1,2, Farid Solaymani-Mohammadi3, Seyed Mohammad Miri4 and Amir Ghaemi5*
Abstract
Oncolytic virotherapy has currently emerged as a promising approach upon which scientists have been able to
induce tumor-specific cell death in a broad spectrum of malignancies. Paramyxoviruses represent intrinsic oncolytic
capability, which makes them excellent candidates to be widely used in oncolytic virotherapy. The mechanisms
through which these viruses destroy the cancerous cells involve triggering the autophagic machinery and
apoptosis in target cells. Interestingly, oncolytic paramyxoviruses have been found to induce autophagy and lead to
tumor cells death rather than their survival. Indeed, the induction of autophagy has been revealed to enhance the
immunogenicity of tumor cells via the release of damage-associated molecular patterns (DAMPs) and the activation
of autophagy-related immunogenic cell death (ICD). Subsequent cross-presentation of tumor-associated antigens
(TAA) through the MHC-I complex to CD8+ T cells results in the productive priming of the tumor-specific immune
response. In this review, we first briefly discuss autophagy and explain the process of viral xenophagy. Finally, we
focus on the interactions between virus and autophagy proteins, elaborating on the global preclinical studies on
oncolytic paramyxoviruses.
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Background
Cancer poses a significant threat to the global health
and is known as the second most common cause of
death after cardiovascular diseases, owing to its high re-
currence and mortality rates which have been estimated
to be nearly 9.6 million deaths in 2018 [1].
Chemotherapy is still the dominant therapeutic ap-
proach for the majority of human invasive malignancies.
However, traditional direct administration of therapeutic
drugs to the patients is no longer applicable due to their
intrinsic limitations including undesirable side effects, un-
favorable pharmacokinetics, and poor bio-distribution.
Thus, development of an efficient weapon with novel
mechanisms of action (MOA), minimal toxicity, and
significant specificity is urgently required to effectively
destroy tumors even after metastasis [2].
Virotherapy has been defined as an emerging thera-
peutic strategy against cancer. Oncolytic viruses (OVs)
in both forms of naturally occurring and genetically
engineered viruses can selectively replicate in and kill
malignant cells without harming healthy ones [3]. Direct
lysis of tumor cells [4] along with indirect induction of
acquired immunity against tumor-specific antigens
(TSAs) are two principal mechanisms through which
OVs play their therapeutical roles. Approval of the first
oncolytic virus (T-Vec, talimogene laherparepvec) by the
US Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) for the treatment of
non-resectable melanoma has provided a novel class of
anti-cancer agents in the field of cancer therapeutics [5].
Regardless of several achievements and also the an-
nouncement of the first commercially available product,
there are many challenges to be addressed in the use of
oncolytic virotherapy for the treatment of patients
suffering from cancer (e.g., high pathogenicity, antiviral
immune responses, and incomplete targeting to all sites
of established tumors). Therefore, development of a new
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generation of virus-related oncolytic therapy for over-
coming these challenges is highly in demand.
The paramyxoviruses (members of the Paramyxoviri-
dae family, order Mononegavirales) are enveloped, non-
segmented negative-sense RNA viruses with 100–300
nm diameter that cause diseases among both animals
and humans [6]. In-vitro studies have shown that the
members of this family (Newcastle disease virus, mea-
sles, morbillivirus, and respiratory syncytial virus) could
naturally replicate and disrupt different tumor cell lines
[7]. Various mechanisms have been proposed for tumor
tropism of oncolytic paramyxoviruses ranging from
overexpression of the viral-specific receptors on can-
cerous cells, cell death due to tumor-specific syncytia
formation, apoptosis, autophagy, and immune cell
death (ICD) to cytotoxic immune effector-induced
cytotoxicity [8].
Autophagy is a crucial biological process during which
a double layer membrane engulfs cytosolic cargo as well
as infectious agents and create autophagosomes in
response to fusion with lysosomes. Although autophagy
plays a fundamental role in degrading during viral
infections, other viruses have evolved several evasion
strategies to escape to escape from the host autophagy
for their own benefit including blocking autophagosome
maturation or degradation or inhibition of autophagy
components [9, 10]. Ultimately, hydrolytic enzymes of
lysosomes degrade and recycle autophagosomal con-
tents. Thus, autophagy is a critical process in cell
growth, control of damage, nutrient starvation, and
other cellular stresses such as oxidative stress and infec-
tion [11]. It also has a vital role in caspase-independent
autophagic cell death through the release of damage-
associated molecular patterns (DAMPs) during viral
infections [12]. A growing body of evidence has revealed
that by incorporation of sophisticated evolved mecha-
nisms during infection, some viruses evade from autoph-
agy and some others hijack autophagy components for
their own replication and spread. Hence, the role of
autophagy as an intracellular protection strategy in viral
infections is totally complicated [13].
This review focuses on oncolytic paramyxoviruses
(Newcastle disease virus, measles, Sendai and morbilli-
virus) and highlights the function of autophagy in the
replication and infection of these viruses as well as the
role of viral proteins in antagonizing or manipulation of
autophagy machinery.
Autophagy
Based on morphological appearance, cell death is catego-
rized into three major types: apoptosis, autophagic cell
death, and necrosis [14]. Autophagy is basically consid-
ered as a catabolic and highly conservative cellular
process [15] which plays a cardinal role in the
maintenance of cellular hemostasis via eliminating the
destructed cellular organelles, exhibiting cytoprotective
effects [16].
In this regard, the aggregates of proteins with the cap-
ability of selective removal of intracellular microbes play
vital roles in xenophagy [17, 18]. Xenophagy initiates
with the recognition of ubiquitin chains expressed on
pathogens, mediated by several receptors such as p62
sequestosome protein or neighbor of breast cancer gene
1 protein (NBR1). The latter is equipped with a
microtubule-associated protein light chain 3 (LC3)-
interacting region (LIR) motif which enables this recep-
tor to interact with ATG8/LC3 and facilitates the target
delivery to autophagosomes [19]. In spite of being a
cytosolic protein, LC3 is covalently linked to phosphati-
dylethanolamine, leading to its localization to autopha-
gosomal membranes and formation of membrane
vesicles [20]. A wide range of stimulants has been pro-
posed to activate autophagy, including deprivation of nu-
trients, oxidative stress, endoplasmic reticulum stress,
and infection with microbial agents [21]. Autophagy
takes place in two distinct stages: 1) formation of phago-
phore or isolation membrane through various cellular
membrane sources, 2) subsequent development of
phagophore membrane, which leads to the formation of
a double—membrane structure, namely autophagosome.
These structures become matured through fusion with
lysosomes and form autolysosomes [22]. Autophagy is
known as a tightly regulated process. It has been demon-
strated that various regulatory factors control the initi-
ation of this phenomenon, including mTOR complex 1
(mTORC1) and AMP-activated kinase (AMPK) [23].
Two principal hallmarks have been proposed to iden-
tify genuine and functional autophagic reactions, 1)
presence of cytoplasmic materials in these reactions, and
2) the peak occurrence in the presence of lysosomal
degradation. More than 30 autophagy-related (ATG)
genes have been identified as playing crucial roles in the
executive process of autophagy. These genes take part in
a number of specific steps of autophagosome biogenesis,
including initiation with UNC-51-like kinase 1 (ULK1)
complex, nucleation of the vesicle with Beclin-1-class III
phosphatidylinositol 3-kinase complex, and elongation
and fusion with microtubule-associated protein light
chain 3 lipidation and sorting nexin 18 (SNX18) com-
plex, respectively [24–28]. ATG12 and ATG8 are two
ubiquitin-like systems of conjugation which belong to
the autophagic machinery and have been conserved in
the course of evolution. The recruitment of these pro-
teins to the membranes of autophagosomes is observed
with their formation, maturation, and development [29].
There are six proteins which belong to the family of
ATG 8 proteins (also known as LC3 proteins), including
LC3A, LC3B, LC3C, GABARAP, GABARAPL1, and
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GATE-16. Cytosol is the place where the unlipidated
form of these ubiquitin-like proteins can often be found.
A number of ATG proteins which activate ubiquiting-
like cascades are required to mediate the conjugation of
LC3 proteins to phosphatidylethanolamine which is
found on the phagophore. In summary, a glycine residue
is exposed following the removal of C-terminal amino
acids before the lipidation of ATG4 protease, being used
in the first steps of ATP-mediated thioester linkage with
a cysteine residue found in E1-like ATG7 [30].
The complex of ATG12 ∼ATG5–ATG16L1 exhibiting
functions resemble to E3 can be constituted during the
second cascade in which ATG12 is involved and makes
covalent E1 ATG7- and E2 ATG10-mediated conjuga-
tion with ATG5. Dimerization of ATG12 ∼ATG5 is
driven by the interaction of ATG16L1 and ATG5. The
WIPI2b acts in the recruitment of complex to phago-
phore. Ultimately, a covalent bond can be established
between LC3 and amine headgroup of PE through the
interaction between ATG12 and ATG3, leading to the
formation of lapidated LC3-II. LC3-II then can act in
the decoration of phagophore’s outer and inner mem-
branes [30].
While autophagy is harnessing powerful cytoprotective
activity, autophagy-triggered cell death is observed in
some cases, which leads to uncontrolled autophagy. LC3
interaction motif (LIM) also know as LC3 interaction re-
gion (LIR) mediate the interaction between autophagy
receptors and ATG8/LC3/GABARAP, allowing for cargo
recognition during selective autophagy [31].
Oncolytic paramyxoviruses and autophagy
Viral xenophagy (virophagy) is defined as an autophagic
reaction which is employed to attack cytoplasmic virions
or their components [32]. Facilitation of viral replication
utilizing autophagic machinery, efficient viral replication
in the presence of impaired autophagic flux, and hin-
dered viral replication are three leading consequences of
virally driven manipulation of autophagy. Indeed, a
number of viruses exhibit various interactions with
autophagy components regarding the host cell type
[13]. For instance, while the HIV Nef protein inhibits
the transition from autophagosome to autolysosome
in macrophages, HIV takes advantage of autophagic
machinery to replicate. This function of Nef protein
helps the virus recover after proteolytic degradation.
As a result, distinct viral pathogenesis is attributed to
different modulatory effects of autophagy on various
strains or serotypes of viruses [33]. Several lines of
evidence have revealed that paramyxoviruses deploy
autophagy as a way to guarantee their replication,
which can be triggered by viral glycoprotein-mediated
membrane fusion. For instance, Human Parainfluenza
Virus 3 (HPIV3) is responsible for autophagosome
maturation blockade [34–36]. Autophagosomes accu-
mulation delineates the equilibrium between their
generation rate and conversion to autolysosomes.
Therefore, during HPIV3 infection, incomplete au-
tophagy is induced through blocking autophagosome-
lysosome fusion and subsequent accumulation of
autophagosomes and suppression of the autophagic
flux. A study by Ding et al. demonstrated that two
SNARE motifs of SNAP29 can mediate the HPIV3
phosphoprotein (P)-SNAP29 interaction which inter-
feres with the phagosome-lysosome fusion, leading to
an effective production of virus particles. A competi-
tive binding of P to SNARE motifs of SNAP29 and
Stx17 was found in this study. As several lines of
evidence have also indicated the pivotal role of other
SNARE proteins in the regulation of autophagosome-
lysosome fusion and also the recruitment of LC3 to
the place where autophagosome forms, a variety of
viruses can take advantage of these proteins to inhibit
the autophagy maturation [37]. It has been well docu-
mented that paramyxoviruses are able to induce the
syncytia creation through which infected cells fuse
with their neighborhood cells and give rise to the
establishment of giant multinucleated cells. The ability
to produce syncytia is another enormous privilege of
the paramyxoviruses which enables them to dissemin-
ate without the release of any mature virus from the
infected cells [38]. In this regard, syncytia formation
highly facilitates the replication of viruses without the
encounter with neutralizing antibodies, which in turn
enhances the potential of paramyxoviruses in provid-
ing efficient viral oncolysis [8]. Besides, immunogenic
syncytia secrete plenty of syncytiosomes, presenting
tumor-associated antigens (TAAs) via MHC molecules
[39, 40]. There is an association between syncytia
death and autophagy. It has been demonstrated that
infection with several members of the family para-
myxoviridae, including Measles virus (MeV), Newcas-
tle disease virus (NDV), and Sendai virus (SeV) is
followed by autophagic programmed cell death [41–
43]. The approved capability of antigen donor cells in
antigen cross-priming, provided by autophagy, gives
rise to the development of TAA-specific or virus-
specific CD8+ T cells, which in turn sheds lights on
the development of novel modalities to upgrade anti-
tumor effects mediated by oncolytic viruses. Further-
more, membrane glycoproteins of paramyxoviruses
with fusion capabilities are shown to vigorously en-
hance the DC-mediated cross-presentation of TAAs
(Fig. 1) [40, 44].
Key oncolytic paramyxoviral proteins in autophagy
In the case of MeV, it has been demonstrated that autoph-
agy induction occurs via three separate routes [45–47].
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The first pathway is related to the CD46 involvement and
is observed only within attenuated strains of MeV, which
results in the induction of autophagy upon virus entry
[48, 49]. The second pathway initiates in a few hours
after infection and occurs along with the expression
of MeV-C protein accompanied by its interaction with
autophagy-regulating immunity-Related GTPase family
M protein (IRGM) [47]. In the final pathway, autoph-
agy is induced through cell-cell fusion, maintaining
both the replication of viral particles and the viability
of syncytia [41]. Accordingly, the relationship between
MeV and autophagy exhibits a high degree of
complexity and therefore, the ability of MeV to take
advantage of autophagy relies on the full occurrence
of this process, which leads to the efficient produc-
tion of viral particles [50].
Nonetheless, with regard to the presence of autophagy
receptors which act in transferring of pathogens to the
autophagy machinery for degradation, the mechanism
through which MeV escapes from degradation by
autophagy has not been fully understood [51]. Autoph-
agy receptors are capable of binding to intracellular
pathogens or their related components, thereby targeting
them toward the development of autophagosomes. LC3
interacting regions (LIR) are parts of the autophagy
receptors which are capable of interaction with small
Ub-like proteins (UBLs) from the ATG8/GABARAP
family. These regions are linked to the lipid phosphati-
dylethanolamine (PE) that is profoundly present in the
autophagosomal membrane. Receptors containing LIR
can make a bridge between the cargo and a group of
proteins that are included in membrane (Atg8/LC3/
GABARAP), allowing the accessibility of the
phagophore-associated autophagic machinery for cargo
[52, 53]. Moreover, Nuclear Domain 10 Protein
(NDP52), optineurin (OPTN), and T6BP have been
elucidated to have a concomitant association with
phagophores’ biogenesis. Recent reports have delineated
the role of NDP52 and OPTN in autophagosomes self-
maturation, leading to the formation of phagosome-
Fig. 1 Oncolytic paramyxoviruses infect and preferentially destroy tumor cells. Following OVs replication, cancerous cells release TAA and DAMPs,
both of which can be recognized by PRRs on APCs leading to the release of inflammatory cytokines. Also, mature APCs present TAAs through
MHC-Ӏ to tumor-specific CD8+ T cells and thereupon, antitumor immune response leads to the lysis of tumor cells via the release of perforin,
granzyme B, and IFN-gamma
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lysosome fusion [54, 55]. As a result, a dual action is
proposed for the proteins mentioned above during xeno-
phagy, including (i) acting as autophagy receptors to fa-
cilitate the autophagy function against pathogens, and
(ii) regulating the fusion of autophagosome to lysosome
in order to mediate the degradation of entrapped patho-
gens. T6BP was also determined to have a similar dual
function, especially during bacterial infections [56].
It has been reported that the interactions between
some specific proteins of autophagy machinery with
several MeV proteins result in the induction of the late
wave of autophagy. Among these interactions, the
alleged targeting of GOPC (Golgi-associated PDZ and
coiled-coil motif-containing protein) by MeV-C does not
influence the infection-induced autophagy [57, 58]. The
possible role of this interaction is to limit the function of
GOPC in already infected cells in order to generate per-
turbation during further autophagy, inducing by newly
entered viruses. At least, two MeV proteins, MeV-C and
MeV-N, have been found to target IRGM (Immunity-Re-
lated GTPase M) and interfere with the regulation of
infection-mediated autophagy. MeV-C protein, which its
overexpression alone has been demonstrated to be suffi-
cient for the IRGM-dependent autophagy induction, is
able to interact with IRGM. Investigations have revealed
that IRGM could interact with a number of autophagy-
associated proteins, which are engaged in the early steps
of autophagy. These proteins include ATG5, ATG10,
LC3C (Light Chain 3 C), SH3GLB1 (SH3 Domain Con-
taining GRB2 Like, Endophilin B1), ULK1, and BECN1
(Beclin 1), all of which could play roles in the induction
of autophagy following the expression of MeV-C protein
[59, 60]. The initiation of autophagosomal membrane
formation has been shown to be highly dependent on
the interaction of IRGM with ULK1 and BECN1 [59].
Following infection with HCV, MeV, and several other
RNA viruses, IRGM is extremely essential for the ULK-1
phosphorylation, which is a crucial process in autophagy
initiation [61]. LC3C is a member of LC3 subfamily,
which is also necessary for the elongation of phagophore
through lipidation with phosphatidylethanolamine.
Additionally, as SH3GLB1 is one of the molecular
switches with the ability to promote autophagosome
formation, it can interact with UVRAG (a regulator of
membrane trafficking during autophagy) and thus facili-
tate the last step of infection-induced autophagy [62]. A
wide spectrum of conditions such as viral infections can
interfere with the ER function and result in unfolding or
misfolding of ER proteins, a phenomenon which is called
ER stress. There is also a process known as unfolded
protein response (UPR), during which ER takes advan-
tage of a set of compatible mechanisms to prevent cell
death complications. In recent years, research has shown
that these pathways may be related to the autophagic
response that plays a key role in cellular response to
inducers of stress [63–65]. NDV is one of these viruses
which can induce autophagy both in vivo and in vitro,
which is beneficial for its replication [66, 67]. Two pro-
teins of NDV, P and NP proteins were shown to induce
autophagy in A549 cells. The capability of these proteins
in altering the hemostasis of ER is mediated by the
upregulation of ER stress marker proteins, GRP78 and
GRP94 [68].
Moreover, it has been shown that the PERK and ATF6
pathways are involved in the regulation of P- and NP-
mediated autophagy induction and knockdown of each
interferes with NDV replication [68].
Furthermore, several studies have indicated the pivotal
role of class III PI3K/Beclin-1 pathway in the NDV-
induced autophagy. This pathway is also highly essential
during the NP- or P-induced autophagy, as the knock-
down of Beclin-1 declines the conversion of LC3 and
degradation of p62 in cells transfected with NP or P
proteins. Expression of these proteins activates the PERK
and ATF6 pathways and leads to partially suppressed au-
tophagic process. These data highlight the remarkable
capability of PERK and ATF pathways in triggering
NDV-induced autophagy. However, as the autophagy
was observed in PERK- or ATF6- knockdown cells, other
pathways may also play a role in the regulation of NDV-
induced autophagy in a manner other than through ER
stress (Fig. 2) [68].
Newcastle disease virus (NDV)
Newcastle disease viruses belong to the Avulavirus
genus, family Paramyxoviridae, and fall into three groups
(velogenic, mesogenic, lentogenic) regarding their patho-
genicity and virulence in the hosts [69]. Several investi-
gations have demonstrated that the velogenic NDV
(MTH68/H, Lasota, PV-701, and 73-T) could specifically
infect and destroy tumor cells.
As briefly discussed above, excessive ER stress is ob-
served in NDV-infected cancer cells, triggering autoph-
agy via PERK/eIF2α, IRE1/JNK, or possible caspase3-
mediated cleavage of eIF2α. IRE1/JNK pathway is in-
volved in the release of beclin-1 and thereby induces the
formation of autophagosomes and facilitates the LC3-II
conversion. Consequently, it can enhance the autophagy
through the attenuation of beclin-1 inhibition, which is
mediated by the downregulation of bcl-2 [70].
A recent study reported the induction of autophagy
following NDV infection in malignant cells. Meng et al.
(2012) first reported that the infection of U251 cells with
NDV boosts the formation of autophagosomes through
the transition from LC3-I to LC3- II. They further re-
ported that the phosphatidylinositol 3-kinase (PI3K)/
Beclin-1 pathway plays an integral role in the induction
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of autophagy by NDV and facilitates the replication of
the virus [67].
In line with previous experiments, we have determined
oncolytic activity of NDV on the TC-1 cells, an E7-
expressing murine tumor model. The results reported that
NDV can suppress growth of tumor cells through trigger-
ing of autophagic cell death via ROS induction [71].
In addition, the induction of autophagy following
NDV infection was investigated in both chicken-derived
fibroblast and primary chicken embryo fibroblast (CEF).
Results of the evaluation of p62/SQSTM1 degradation,
LC3-II turnover, and GFP-LC3 signal revealed that the
NDV infection could induce autophagy in these cells.
Indeed, this virus takes advantage of autophagy for a
more efficient replication [72]. In another study,
pharmacologic modulation of autophagy was assessed
aiming to enhance the oncolytic potential of NDV strain
FMW (NDV/FMW) in drug-resistant lung cancer cells
(A549 resistance to cisplatin or paclitaxel). The results
indicated that the NDV/FMW induces autophagy
through the modification of PI3K/Akt/mTOR/p70S6K
pathway. Combination of chloroquine or rapamycin with
NDV significantly promoted the oncolytic efficiency of
NDV/FMW in mice bearing the drug-resistant lung can-
cer [73]. Research on lung cancer stem cells (CSCs) also
demonstrated that the NDV-FMW induces autophagy
process in these cells through the (LC3) II and P62
degradation as well as inhibition of the AKT/mTOR
pathway, offering these viruses as novel and promising
modalities for cancer treatment (Table 1) [74].
NDV induces autophagy-mediated immunogenic cell death
Immunogenic cell death (ICD) is referred to as changes
in cell surface compositions (i.e., calreticulin) which re-
sult in the secretion of soluble mediators such as ATP,
high-mobility group box 1 protein (HMGB1), and Heat
shock proteins (HSP) HSP70/90. Following these
changes, dendritic cells (DCs) could be activated and
present antigens to T cells. Once tumor cells were
infected with oncolytic viruses, the release of pathogen-
associated molecular patterns (PAMPs), tumor-
associated antigens (TAAs), and damage-associated
molecular patterns (DAMPs) could induce ICD and give
rise to stronger immune response (Fig. 1) [75–77].
As mentioned above, apoptosis, autophagic cell death,
necroptosis, and ER stress are among the phenomena in-
volved in the induction of ICD following exposure to
various stimuli. Preclinical experiments and clinical trials
have revealed that the oncolytic NDV exhibits strong
anti-tumor function. While this virus is shown to induce
apoptosis, autophagy-related cell death, and necroptosis
in various types of cancers, a current study on glioma
cells indicated the NDV-induced Immunogenic cell
death [78].
Fig. 2 Several NDV and MeV proteins interact with autophagy-related proteins and thereby play a key role in the induction of autophagy in
tumor cells. This lysosomal degradation takes place upon several stages, including nucleation, the formation of phagosomes, autophagosomes,
and autolysosome
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A study on glioblastoma multiforme cell lines (GL261)
in xenotransplant models showed that the infection of
tumor cells with NDV leads to the elevated level of cell
surface calreticulin as well as the increased secretion of
HMGB1 and PMEL17 tumor antigens. Following vir-
otherapy, the results revealed a population growth
among IFN-gamma+ CD4+/CD8+ T cells in the tumor
microenvironment along with a decline in the number
of myeloid-derived suppressor cells (MDSCs) [79].
A recent study (Ye et al. 2018) indicated that the
oncolytic NDV mediates ICD in the lung cancer cells.
Additionally, the infection of lung cancer cells with
NDV could increase the levels of ATP, HSP70/90, and
HMGB1 in cell supernatant. Moreover, confocal and
immunoblotting analyses revealed that the expression of
calreticulin is up-regulated in lung cancer cells [78].
Finally, administration of oncolytic NDV was shown to
inhibit the tumor cells growth through the activation of
antitumor immune responses and also the release of
inflammatory cytokines (Table 1).
Measles virus (MeV)
Measles virus belongs to the genus Morbillivirus in the
family Paramyxoviridae. Measles is a highly transmissible
infectious disease and is one of the most important
causes of global death among young children [80]. The
disease is caused by the measles virus and remains a sig-
nificant cause of child mortality in developing countries
[81]. Most in vitro studies and preclinical trials on onco-
lytic measles virus have used the attenuated vaccine
Edmonston strain, which is derived from the common
wild-type measles virus and is observed to have minimal
side effects. Edmonston strain selectively replicates in
and destroys neoplastic cells [82]. The oncoselectivity of
Measles virus is chiefly based on the overexpression of
the CD46 receptor on malignant cells [83]. Therefore,
Measles virus is potential for the constitution of a com-
petent, safe oncolytic group. Besides, the oncolytic virus
activates the sequestosome 1(SQSTM1/p62)-mediated
autophagic machinery to reduce the mitochondrion-
tethered mitochondrial antiviral signaling protein (mito-
phagy) and then abrogates the innate immune response
in nonsmall cell lung cancer (NSCLC) cells which results
in enhancement of viral propagation. The results evinced
that autophagy inducers could enhance the antitumor
efficacy of virotherapy [84]. In another study, it was
determined that autophagy contributes to the regulation
of Measles virus vaccine strain Edmonston, B-induced
nonapoptotic cell death, and oncolysis [85]. Moreover, it
was determined that HeLa cell infection with oncolytic
measles virus is associated with the autophagosome ac-
cumulation via the engagement of the CD46-Cyt-1/
GOPC pathway. Investigation of the molecular pathways
and autophagy kinetics by evaluation of ATG5 expres-
sion led to the discovery of two continuous waves of au-
tophagy, the early wave and the late one. The results
Table 1 The interactions between oncolytic paramyxoviruses and autophagy pathway
Virus . Proteins induce
autophagy
Cell/Tumor model Autophagy/ ICD induction Citation (s)
Newcastle disease
virus
NP/P U251 LC3-I to LC3- II conversion Meng et al. (2012)
CEF, DF-1 LC3-I to LC3- II conversion Sun et al. (2014) [72]
A549 resistant to cisplatin PI3K/Akt/mTOR/p70S6K pathway Jiang et al. (2014) [73]
Lung cancer stem cells (CSCs) Degradation of (LC3) II and P62 proteins,
inhibition of the AKT/mTOR pathway
Hu et al. (2015) [74]
GL261 Calreticulin surface exposure, the release
of HMGB1 and increase in PMEL17
cancer antigen expression.
Koks et al. (2014) [79]
A549, H1650, H460 Induction of secreted HMGB1
and HSP70/90 release.
Ye et al. (2018) [78]
Measles virus C/N NSCLC
NSCLC
Triggering SQSTM1/p62-mediated
mitophagy
Xia et al. (2014) [84]
Hela Induction of autophagy through cellular
receptor CD46 and the scaffold
protein GOPC
Richetta et al. (2013) [41]
Sendai virus NA NSCLC, Hela, A549 Triggering autophagy through
the PI3K/Akt/mTOR/p70S6K pathway
Zhang (2015) [88]
and Wang (2018) [89] et al.
PC3 Triggering autophagy through the JNK,
p38, and PI3K/beclin-1 pathway
Miao et al. (2018) [89]
Calu-3 Induced necrosis Zhirnov [90]
morbillivirus NA Vero Vps34/beclin1 autophagic complex Delpeut et al. (2012) [35]
NSCLC non-small cell lung cancer, PC3 human prostate cancer cell line, Calu-3 human lung cancer cell line, NP/P nucleocapsid protein/ phosphoprotein, C/N non-
structural C/ nucleocapsid protein, NA not available
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explained that different molecular mechanisms contrib-
ute to the autophagy induction after treatment with
oncolytic measles virus vaccine strain Edmonston
(Table 1) [41].
Other members
Hemagglutinating virus of Japan envelope (HVJ-E; sen-
dai virus) is an RNA virus, belonging to family Paramyx-
oviridae, genus and species Respirovirus [86]. Sendai
virus, also recognized as Murine parainfluenza virus
comprises the Human parainfluenza virus 3, Bovine
parainfluenza virus 3, and Human parainfluenza virus 1
species [87]. It has been demonstrated that oncolytic
HVJ-E induces both apoptosis and autophagy in non-
small cell lung cancer cell (NSCLC). The results re-
ported that the HVJ-E-induced autophagy is triggered
and modulated by inhibition of the class I PI3K/Akt/
mTOR/p70S6K pathway that negatively regulates au-
tophagy [88]. Furthermore, it was shown that extracellu-
lar signal-regulated kinase (ERK) and the PI3K/Akt/
mTOR/p70S6K pathways contribute to oncolytic HVJ-E-
induced autophagy in infected HeLa cells [89]. Miao and
colleagues tried to investigate the HVJ-E-mediated au-
tophagy and apoptosis with the focus on prostate cancer
(PC3) cells and also to identify the potential mechanisms
that facilitate these processes. In total, HVJ-E was found
to several pathways such as JNK, p38, and PI3K/beclin-1
in the studied cells in a ROS-mediated manner, leading
to the occurrence of autophagy and apoptosis. These
findings broaden the horizon about understanding the
strategies through which HVJ-E could act as an antitu-
mor agent and pave the way for establishing effective
therapeutic modalities against cancer [90]. Another work
attempted to evaluate the induction of apoptosis, necro-
sis, and autophagy pathways following SeV infection in
Calu-3 cell lines. Viruses were shown to activate differ-
ent pathways which take part in the induction of cell
death. There was particular characteristics representative
of necrosis including cellular swelling and failure in
several processes such as chromatin DNA laddering,
activation of caspase 3 and 8 pathways, and cleavage of
PARP protein. There was also the activated Akt (a pro-
tein kinase with antiapoptotic activity). This study also
showed that the intracellular autopghagic machinery in
SeV-infected cells correlated with type of death. Specific-
ally, there was association between suppressed apoptosis
and the induction of autophagy. Therefore, SeV-infected
cells lacked apoptosis while representing autophagy in a
considerable level. SeV-induced necrosis was also found
for the first time the studied cell line [91].
Products of IFN stimulated genes (ISG) play immuno-
regulatory roles and can also trigger antiviral immune
responses. These products also affect the innate immune
responses through manipulation and regulation of
autophagy. Two strategies have been suggested: 1) play-
ing role in the development of autophagy-based acquired
antiviral immune responses or preventing viral agents
from utilizing autophagy for their benefit, and 2) attack-
ing paramount molecules responsible for antiviral
immune responses which lead to a specified activation
of autophagy and thereby acting as the regulators of
IFN-induced responses against viruses [92].
IFN-β and ISGs are shown to be induced following
paramyxoviruses infection in a transcriptional level,
whose proteins can specifically interrupt several steps of
the virus life cycle and hinder viral particle development.
In a study by Subramanian et al. Tudor domain contain-
ing 7 (TDRD7) block the replication of SeV. This ISG is
demonstrated to hamper the function of adenosine 5ˊ-
monophosphate-activated protein kinase (AMPK) and
thereby prevent the SeV from development of autoph-
agy. AMPK stimulate the autophagic machinery via
mTORC1 suppression and ULK1 activation [93].
Canine distemper virus (CDV) is a globally distributed
pantropic morbillivirus. Morbilliviruses infect the
immune cells and then spread to the epithelial cells. The
viral hemagglutinin glycoprotein attaches and enters into
the target cells after glycoprotein-mediated membrane
fusion [94].
The role of autophagy in mouse-adapted canine
distemper virus infection was evaluated and it was
shown that viral glycoprotein-mediated membrane
fusion correlates with enhanced autophagy and LC3
punctum formation in induced multinucleated cells,
suggesting that the formation of syncytia, in turn, trig-
gers autophagy and efficient viral propagation in virally
infected cells (Table 1) [35].
Conclusion
In the past decade, considerable progress has been made
in understanding the complex interactions between au-
tophagy and paramyxoviruses in both in vivo and in
vitro experimental systems. The cancer cell selectivity
and tumor cell death induction make oncolytic viruses-
based therapy a promising tool for cancer therapy.
Oncolytic paramyxoviruses, via positive regulation of au-
tophagy as well as the release of damage-associated mo-
lecular patterns (DAMPs) and tumor-associated antigens
(TAA) from tumor cells, potentially stimulate the innate
and tumor- specific adaptive immune responses and
could be designed for clinical autophagy-based, thera-
peutic approaches. Currently, a few clinical trials are on-
going to evaluate the effect of oncolytic virus-modulated
autophagy in the treatment of human cancers.
In this review, we have focused primarily on distinct
paramyxoviruses that interact with the autophagy
pathway. Pre-clinical studies performed on oncolytic
paramyxoviruses have demonstrated that the PI3K/Akt/
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mTOR/p70S6K pathway plays a critical role in autoph-
agy and immunogenic cell death (ICD) in cancerous
models. Thus, precise identification of the ways through
which oncolytic paramyxoviruses induce autophagy and
ICD can pave the way for improvement of their anti-
cancer therapeutic potential and provided a basis for the
development of a potential combinational therapeutic
approaches using oncolytic paramyxoviruses and au-
tophagy modulators.
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